Publications by authors named "Jingjing Schneider"
Peripheral neuropathy (PN) is a significant cause of morbidity associated with Waldenström macroglobulinemia (WM). The phase 3 ASPEN study compared the efficacy and safety of zanubrutinib with ibrutinib in patients with WM. This ad hoc analysis examined treatment outcomes with zanubrutinib or ibrutinib on PN symptoms associated with WM in patients enrolled in ASPEN.
View Article and Find Full Text PDFArticle Synopsis
- The phase 3 ASPEN trial compared the effectiveness of two BTK inhibitors, zanubrutinib and ibrutinib, in treating Waldenström macroglobulinemia, analyzing genetic mutations' impact on treatment response.
- The study found that patients with mutations in CXCR4 and TP53 had poorer responses and survival rates but those treated with zanubrutinib generally showed better outcomes than those given ibrutinib.
- Overall, the research indicated that zanubrutinib offers improved clinical outcomes for patients with specific mutations compared to ibrutinib, highlighting the importance of genetic testing in treatment decision-making.
Article Synopsis
- The phase III ASPEN study showed that zanubrutinib is as effective as ibrutinib but has better safety for treating patients with Waldenström macroglobulinemia (WM).
- In a long-term follow-up, zanubrutinib demonstrated higher rates of very good partial response and complete response compared to ibrutinib in both cohorts of WM patients.
- Adverse events like diarrhea, muscle spasms, and hypertension were more common with ibrutinib, while zanubrutinib had a lower risk of treatment-related discontinuation.
In competitive business, such as insurance and telecommunications, customers can easily replace one provider for another, which leads to customer attrition. Keeping customer attrition rate low is crucial for companies, since retaining a customer is more profitable than recruiting a new one. As a main statistical process control (SPC) method, the CUSUM scheme is able to detect small and persistent shifts in customer attrition.
View Article and Find Full Text PDFArticle Synopsis
- * The ASPEN study compared zanubrutinib with ibrutinib in patients with the MYD88 mutation and included a separate group of MYD88WT patients receiving only zanubrutinib.
- * In the MYD88WT cohort of 26 patients, 27% achieved a very good partial response, and overall survival rates at 18 months were 88%, indicating that zanubrutinib could be an effective treatment for this patient group despite
Zanubrutinib (BGB-3111) is a next-generation Bruton tyrosine kinase inhibitor designed to be more selective with fewer off-target effects. We conducted a phase 1 study to assess the safety of its combination with obinutuzumab and evaluate early efficacy in 81 patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) or relapsed/refractory (R/R) follicular lymphoma (FL). In this phase 1b study, zanubrutinib was tolerable at 160 mg twice daily or 320 mg once daily combined with IV obinutuzumab in patients with CLL/SLL (n = 45) and FL (n = 36).
View Article and Find Full Text PDFArticle Synopsis
- Bruton tyrosine kinase (BTK) inhibition is an important treatment for Waldenström macroglobulinemia (WM), and the ASPEN study compared ibrutinib and zanubrutinib, two BTK inhibitors, in patients with the disease.
- In the study, while no patients achieved a complete response, a similar percentage of patients (28% with zanubrutinib vs. 19% with ibrutinib) reached a very good partial response, indicating both drugs are effective but showing no significant difference between them.
- Zanubrutinib showed a trend toward better response quality and lower rates of adverse effects, particularly cardiovascular issues, although some patients experienced higher rates of neutropenia compared to
Background: Lipoprotein apheresis (LA) can effectively lower lipoproteins but is an invasive procedure.
Objective: The objective of this study was to evaluate whether evolocumab can reduce LA requirement in patients undergoing chronic LA.
Methods: Patients on regular weekly or every-2-week LA and moderate- to high-intensity statin (if tolerated) with pre-LA low-density lipoprotein cholesterol (LDL-C) levels ≥2.
Background Findings from clinical trials of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors have led to concern that these drugs or the low levels of low-density lipoprotein (LDL) cholesterol that result from their use are associated with cognitive deficits. Methods In a subgroup of patients from a randomized, placebo-controlled trial of evolocumab added to statin therapy, we prospectively assessed cognitive function using the Cambridge Neuropsychological Test Automated Battery. The primary end point was the score on the spatial working memory strategy index of executive function (scores range from 4 to 28, with lower scores indicating a more efficient use of strategy and planning).
View Article and Find Full Text PDFSome observational studies raised concern that statins may cause memory impairment, leading to a US Food and Drug Administration warning. Similar questions were raised regarding proprotein convertase subtilisin/kexin-type 9 inhibitors (PCSK9i) and neurocognitive function. No prospectively designed study has evaluated the relationship between long-term PCSK9i use and cognition changes.
View Article and Find Full Text PDF